General Information and Variability Data of DT
DT ID DTD0028
Gene Name SLC47A2
Protein Name Multidrug and toxin extrusion protein 2
Synonyms Kidney-specific H(+)/organic cation antiporter; MATE-2; MATE2; MATE2-B; MATE2-K; MATE2K; SLC47A2; Solute carrier family 47 member 2; hMATE-2
Gene ID
146802
UniProt ID
Q86VL8
TCDB ID
2.A.66.1.20
DT Family Multidrug/Oligosaccharidyl-Lipid/Polysaccharide (MOP) Flippase Superfamily
Multi Antimicrobial Extrusion (MATE) Family
Tissue Specificity Isoform 3 is predominantly expressed inkidney. Isoform 6 is expressed in brain.
Function This transporter is reesponsible for the secretion of cationic drugs across the brush border membranes, such as tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide, metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, and ganciclovir.
Disease(s) Cytomegalovirus infections [ICD-11: 1D82]
Ovarian cancer [ICD-11: 2C73]
Type 2 diabetes [ICD-11: 5A11]
Ventricular arrhythmias [ICD-11: BC71]
Herpes simplex virus infection [ICD-11: 1F00]
Maintenance of normal sinus rhythm [ICD-11: BC81.3]
Genetic Polymorphisms & Epigenetic Regulations of DT
Species-, Tissue- and Disease-specific Protein Abundances of DT
Exogenous Factor Altering DT Activity
Approved Drug(s) Transported by This DT Abemaciclib Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [1]
Acyclovir Drug Info Shingles [ICD-11: 1.00E+91] Approved [2]
Cimetidine Drug Info Acid reflux disorder [ICD-11: DA22] Approved [2]
Dofetilide Drug Info Maintenance of normal sinus rhythm [ICD-11: BC81.3] Approved [3]
Estrone sulfate Drug Info Menopausal symptoms [ICD-11: MF32] Approved [2]
Ganciclovir Drug Info Cytomegalovirus infections [ICD-11: 1D82] Approved [2]
Metformin Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [2]
Procainamide Drug Info Ventricular arrhythmias [ICD-11: BC71] Approved [2]
Topotecan Drug Info Ovarian cancer [ICD-11: 2C73] Approved [2]
Clinical Trial Drug(s) Transported by This DT Tetraethylammonium Drug Info Hyperlipidaemia [ICD-11: 5C8Z] Phase 2 [2]
Withdrawn, Discontinued or Preclinical Drug(s) Transported by This DT N-methylpyridinium Drug Info Colon cancer [ICD-11: 2B90.Z] Preclinical [2]
Endogenous Substrate(s) H+
Endogenous Metabolites (EMs) Handled by This DT Creatinine EM Info Identified using HEK293 cells-MATE2 [4]
Guanidine EM Info Identified using HEK293 cells-MATE2 [4]
Testosterone EM Info Unclear experiment used for identifying this EM [5]
Thiamine EM Info Identified using HEK293 cells-MATE2 [4]
Drug-DT Affinity Assessed by Cell Line
Drug(s) with Drug-DT Affinity Data Acyclovir Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 4320 microM [2]
Cimetidine Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 120 microM [2]
Cimetidine Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 370 microM [4]
Estrone sulfate Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 850 microM [2]
Ganciclovir Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 4280 microM [2]
Metformin Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 1050 microM [4]
Metformin Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 1980 microM [2]
N-methylpyridinium Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 93.5 microM [4]
N-methylpyridinium Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 110 microM [2]
Procainamide Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 1580 microM [2]
Procainamide Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 4100 microM [4]
Tetraethylammonium Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 760 microM [2]
Tetraethylammonium Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 830 microM [4]
Topotecan Drug Info Human embryonic kidney cells (HEK293)-MATE2K Km = 60 microM [2]
References
1 Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
2 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
3 FDA Drug Development and Drug Interactions
4 Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006 Aug;17(8):2127-35.
5 Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007 Jul;24(7):1227-51.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.